Copy to clipboard 
CONMED reported 4Q25 orthopedic sales of $157.3 million, up 13.2% compared to the fourth quarter of 2024. For the full year, the company generated $574.5 million in orthopedic sales, up 5.6% compared to the prior year.
The company spent recent quarters underperforming relative to the overall sports medicine market, but turned its fortunes around in the fourth quarter with more than 13% orthopedic growth. CONMED attributed the change to four main factors: steady commercial execution, the continuing adoption of BioBrace, better supply chain health, and international approvals for products.
“We ended the year with our back order value and number of SKUs on back order at a three-year low, and we continue to make additional progress in the first quarter,” said CONMED CEO Pat Beyer. “We are not yet at our goal of operating a world-class supply chain, but we have made significant progress and are at a point where our salesforce can once again be proactive with our growth drivers.”
While CONMED does not provide orthopedic-specific guidance, its mid-term expectation for sports medicine growth is between 4% and 8%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 4Q25 | 4Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $15.1 | $13.5 | $1.6 | 12% |
| Sports Medicine | $142.2 | $125.5 | $16.7 | 13.3% |
| Total | $157.3 | $139.0 | $18.3 | 13.2% |
| Segment | FY25 | FY24 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $53.1 | $48.1 | $4.9 | 10.2% |
| Sports Medicine | $521.4 | $495.8 | $25.6 | 5.2% |
| Total | $574.5 | $543.9 | $30.6 | 5.6% |
Orthopedic Sales by Geography
| Region | 4Q25 | 4Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $58.3 | $54.7 | $3.6 | 6.6% |
| OUS | $99.0 | $84.3 | $14.8 | 17.5% |
| EMEA | $38.6 | $34.1 | $4.5 | 13.2% |
| APAC | $33.8 | $27.4 | $6.4 | 23.5% |
| ROW | $26.6 | $22.7 | $3.8 | 16.8% |
| Total | $157.3 | $139.0 | $18.3 | 13.2% |
| Region | FY25 | FY24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $215.0 | $210.7 | $4.3 | 2% |
| OUS | $359.5 | $333.3 | $26.3 | 7.9% |
| EMEA | $141.1 | $131.1 | $10.0 | 7.6% |
| APAC | $126.3 | $117.7 | $8.6 | 7.3% |
| ROW | $92.1 | $84.5 | $7.7 | 9.1% |
| Total | $574.5 | $543.9 | $30.6 | 5.6% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $373.2 | |
| Cost of Sales | $154.9 | 41.5% |
| Selling and Admin | $166.8 | 44.7% |
| R&D | $14.9 | 4% |
| Other | $19.9 | 5.3% |
| Net Earnings | $16.7 | 4.5% |
CONMED reported 4Q25 orthopedic sales of $157.3 million, up 13.2% compared to the fourth quarter of 2024. For the full year, the company generated $574.5 million in orthopedic sales, up 5.6% compared to the prior year.
The company spent recent quarters underperforming relative to the overall sports medicine market, but turned its fortunes...
CONMED reported 4Q25 orthopedic sales of $157.3 million, up 13.2% compared to the fourth quarter of 2024. For the full year, the company generated $574.5 million in orthopedic sales, up 5.6% compared to the prior year.
The company spent recent quarters underperforming relative to the overall sports medicine market, but turned its fortunes around in the fourth quarter with more than 13% orthopedic growth. CONMED attributed the change to four main factors: steady commercial execution, the continuing adoption of BioBrace, better supply chain health, and international approvals for products.
“We ended the year with our back order value and number of SKUs on back order at a three-year low, and we continue to make additional progress in the first quarter,” said CONMED CEO Pat Beyer. “We are not yet at our goal of operating a world-class supply chain, but we have made significant progress and are at a point where our salesforce can once again be proactive with our growth drivers.”
While CONMED does not provide orthopedic-specific guidance, its mid-term expectation for sports medicine growth is between 4% and 8%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 4Q25 | 4Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $15.1 | $13.5 | $1.6 | 12% |
| Sports Medicine | $142.2 | $125.5 | $16.7 | 13.3% |
| Total | $157.3 | $139.0 | $18.3 | 13.2% |
| Segment | FY25 | FY24 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $53.1 | $48.1 | $4.9 | 10.2% |
| Sports Medicine | $521.4 | $495.8 | $25.6 | 5.2% |
| Total | $574.5 | $543.9 | $30.6 | 5.6% |
Orthopedic Sales by Geography
| Region | 4Q25 | 4Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $58.3 | $54.7 | $3.6 | 6.6% |
| OUS | $99.0 | $84.3 | $14.8 | 17.5% |
| EMEA | $38.6 | $34.1 | $4.5 | 13.2% |
| APAC | $33.8 | $27.4 | $6.4 | 23.5% |
| ROW | $26.6 | $22.7 | $3.8 | 16.8% |
| Total | $157.3 | $139.0 | $18.3 | 13.2% |
| Region | FY25 | FY24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $215.0 | $210.7 | $4.3 | 2% |
| OUS | $359.5 | $333.3 | $26.3 | 7.9% |
| EMEA | $141.1 | $131.1 | $10.0 | 7.6% |
| APAC | $126.3 | $117.7 | $8.6 | 7.3% |
| ROW | $92.1 | $84.5 | $7.7 | 9.1% |
| Total | $574.5 | $543.9 | $30.6 | 5.6% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $373.2 | |
| Cost of Sales | $154.9 | 41.5% |
| Selling and Admin | $166.8 | 44.7% |
| R&D | $14.9 | 4% |
| Other | $19.9 | 5.3% |
| Net Earnings | $16.7 | 4.5% |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
